RND3 and myeloid sarcoma: Interestingly, when examining the TIM-1 and TIGIT expressing memB cell subsets, the only population to show significant differences in frequency between responders and non-responders was the DP memB subset which was increased in the responder MS patient group that did not show increased EDSS after anti-CD20 treatment.